# Teva Pharmaceutical (TEVA) — Earnings

TEVA · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/teva/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.02 |
| EPS estimate | $0.05 |
| EPS surprise | −60.04% |
| Revenue surprise | +6.50% |
| Revenue | $4.3B |
| Revenue estimate | $4.0B |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) |

Teva reported Q2 2026 results on July 29, 2026. Earnings per share were $0.02, short of the $0.05 estimate by 60.04%. Revenue of $4.3 billion beat the $4.0 billion consensus by 6.50%. Compared with Q2 2025, EPS fell from $0.66, while revenue rose from $4.2 billion. The quarter's EPS was the lowest in the table, down from $0.50 in Q1 2026.

Earlier years were steady. Annual EPS was $2.53 in 2022, $2.56 in 2023, $2.49 in 2024 and $2.89 in 2025. Annual revenue rose each year, from about $15.0 billion in 2022 to about $17.2 billion in 2025. Q4 2025 set the revenue high in the table at $4.6 billion, and Q4 2023 the EPS high at $1.00. The first half of 2026 adds up to $0.52 per share, against $1.18 a year earlier. Over the last 20 quarters, Teva topped the EPS estimate 13 times. Apart from Q2 2026, the largest miss was Q1 2023, at 28.19%.

Teva reported Q3 between November 3 and November 8 in each of the past four years. That points to early November 2026 for the next report. It will show whether earnings move back toward the levels of earlier quarters.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | $0.05 | $0.02 | -60.04% | $4.0B | $4.3B |
| Q1 2026 | Apr 29, 2026 | $0.46 | $0.50 | 9.42% | $3.8B | $3.8B |
| Q4 2025 | Jan 28, 2026 | $0.64 | $0.93 | 45.47% | $4.3B | $4.6B |
| Q3 2025 | Nov 5, 2025 | $0.69 | $0.78 | 13.03% | $4.4B | $4.5B |
| Q2 2025 | Jul 30, 2025 | $0.62 | $0.66 | 7.02% | $4.3B | $4.2B |
| Q1 2025 | May 7, 2025 | $0.46 | $0.52 | 12.43% | $4.0B | $3.9B |
| Q4 2024 | Jan 29, 2025 | $0.71 | $0.71 | 0.38% | $4.1B | $4.2B |
| Q3 2024 | Nov 6, 2024 | $0.66 | $0.69 | 4.34% | $4.1B | $4.3B |
| Q2 2024 | Jul 31, 2024 | $0.55 | $0.61 | 10.51% | $4.1B | $4.2B |
| Q1 2024 | May 8, 2024 | $0.51 | $0.48 | -6.58% | $3.7B | $3.8B |
| Q4 2023 | Jan 31, 2024 | $0.77 | $1.00 | 30.29% | $4.0B | $4.5B |
| Q3 2023 | Nov 8, 2023 | $0.61 | $0.60 | -1.28% | $3.7B | $3.9B |
| Q2 2023 | Aug 2, 2023 | $0.53 | $0.56 | 6.63% | $3.7B | $3.9B |
| Q1 2023 | May 10, 2023 | $0.56 | $0.40 | -28.19% | $3.6B | $3.7B |
| Q4 2022 | Feb 8, 2023 | $0.72 | $0.71 | -0.70% | $3.9B | $3.9B |
| Q3 2022 | Nov 3, 2022 | $0.62 | $0.59 | -4.21% | $3.8B | $3.6B |
| Q2 2022 | Jul 26, 2022 | $0.58 | $0.68 | 16.96% | $3.8B | $3.8B |
| Q1 2022 | May 3, 2022 | $0.55 | $0.55 | 0.16% | $3.7B | $3.7B |
| Q4 2021 | Feb 9, 2022 | $0.73 | $0.77 | 4.93% | $4.3B | $4.1B |
| Q3 2021 | Oct 27, 2021 | $0.64 | $0.59 | -8.47% | $4.0B | $3.9B |

## Frequently Asked Questions

### When did Teva Pharmaceutical (TEVA) last report earnings?

Teva Pharmaceutical last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did TEVA beat earnings estimates?

No. Teva Pharmaceutical reported EPS of $0.02 for Q2 2026 against a $0.05 estimate — a 60.04% miss.

### How much revenue did TEVA report last quarter?

Teva Pharmaceutical reported $4.3B in revenue for Q2 2026, against a consensus estimate of $4.0B.

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).